Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis

被引:13
|
作者
Liang, Shuolin [1 ]
Qin, Qiuhong [2 ]
Tang, Yulan [1 ]
Liao, Weijing [3 ]
Yang, Yi [1 ]
He, Jinrong [1 ]
Li, Liangsheng [1 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Neurol, Nanning 530021, Peoples R China
[2] Guangxi Med Univ, Dept Histol, Nanning 530021, Peoples R China
[3] Guangxi Med Univ, Affiliated Wuming Hosp, Dept Neurol, Nanning 530199, Peoples R China
基金
中国国家自然科学基金;
关键词
Blood-brain barrier (BBB); neuromyelitis optic spectrum disorders; newly diagnosis; optic neuritis; albumin quotient (qalb); T-CELLS; MULTIPLE-SCLEROSIS;
D O I
10.21037/apm.2019.12.12
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Blood-brain barrier (BBB) disruption and ensuing immune activation are central to the pathogenesis of central nervous system (CNS) inflammatory diseases. However, the influence of BBB permeability on the clinical signs and prognosis of newly diagnosed neuromyelitis optica spectrum disorder (NMOSD) has not been examined. We investigate the relationships between BBB permeability as showed by the albumin quotient (qalb) and clinical features of NMOSD. Methods: Demographic and clinical data of 46 patients, including peripheral blood (PB) measures (serum albumin concentration and total leukocyte, neutrophil, total lymphocyte, CD4+ T cell, and CD8+ T cell counts, complement C3 and C4 concentrations, AQP4-IgG titer),autoimmune antibody titers (ANA/SSA/SSB/ Ro-52), and cerebrospinal fluid (CSF) parameters (total leukocyte count, total protein and albumin concentrations, AQP4-IgG titer), were compared between qalb(BBB permeability) increased and normal groups. Complete measures were not obtained from 9 patients, but all other measures were included in the analysis. Results: According to the calculated qalb, 15 patients with albumin quotient (qalb) > (4 + age/15) x 10(-3) were assigned to the qalb increased (high BBB permeability) group (33%) and the remainder to the qalb normal group. Compared to the qalb normal group, the qalb increased group exhibited significantly lower serum albumin (P=0.001) and CD4+ T cell count (P=0.044), CD8+ T cell count (P=0.014), and total T lymphocyte count (P=0.016). The qalb increased group proved higher CSF albumin, total protein, leukocyte count, and IgG titer (all P=0.000). Optic neuritis and optic nerve abnormalities on magnetic resonance images were also more frequent in the qalb increased group (P=0.037 and 0.038, respectively). Patients in the qalb increased group showed significantly poorer treatment response as indicated by the lower post-treatment change in Expanded Disability Status Scale (EDSS) score compared to the qalb normal group. Conclusions: BBB permeability is strongly associated with the clinical features and treatment response of newly diagnosed NMOSD. The qalb is a potentially valuable indicator of disease severity and an index to guide personalized treatment.
引用
收藏
页码:324 / 330
页数:7
相关论文
共 50 条
  • [1] Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis optica spectrum disorder patients
    You Xiaofan
    Yan Lirong
    Li Xin
    Pang Ying
    Guo Xiaolei
    Ye Jing
    Hu Hongtao
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 27 : 254 - 259
  • [2] Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
    Asgari, Nasrin
    Flanagan, Eoin P.
    Fujihara, Kazuo
    Kim, Ho Jin
    Skejoe, Hanne P.
    Wuerfel, Jens
    Kuroda, Hiroshi
    Kim, Su Hyun
    Maillart, Elisabeth
    Marignier, Romain
    Pittock, Sean J.
    Paul, Friedemann
    Weinshenker, Brian G.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (04):
  • [3] Neutrophils mediate blood-brain barrier disruption in a rat model of neuromyelitis optica
    Winkler, A.
    Wrzos, C.
    Bennett, J. L.
    Stadelmann, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 174 - 175
  • [4] Early breakdown of the blood-brain barrier in a model of neuromyelitis optica
    Winkler, Anne
    Wrzos, Claudia
    Brueck, Wolfgang
    Bennett, Jeffrey L.
    Nessler, Stefan
    Stadelmann, Christine
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 34 - 35
  • [5] Different blood-brain barrier disruption profile in multiple sclerosis, neuromyelitis optica spectrum disorders and neuropsychiatric systemic lupus erythematosus
    Kalinowska-Lyszczarz, A.
    Pawlak, M. A.
    Wyciszkiewicz, A.
    Jasiak-Zatonska, M.
    Wiesik-Szewczyk, E.
    Pawlak-Bus, K.
    Leszczynski, P.
    Kozubski, W.
    Michalak, S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 845 - 846
  • [6] Increased Serum Matrix Metalloproteinase-9 in Neuromyelitis Optica; Implication of Disruption of Blood-Brain Barrier
    Hosokawa, Takafumi
    Nakajima, Hideto
    Doi, Yoshimitsu
    Sugino, Masakazu
    Kimura, Fumiharu
    Hanafusa, Toshiaki
    Takahashi, Toshiyuki
    NEUROLOGY, 2010, 74 (09) : A167 - A167
  • [7] Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood-brain barrier
    Hosokawa, Takafumi
    Nakajima, Hideto
    Doi, Yoshimitsu
    Sugino, Masakazu
    Kimura, Fumiharu
    Hanafusa, Toshiaki
    Takahashi, Toshiyuki
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 236 (1-2) : 81 - 86
  • [8] Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica
    Shimizu, Fumitaka
    Schaller, Kristin L.
    Owens, Gregory P.
    Cotleur, Anne C.
    Kellner, Debra
    Takeshita, Yukio
    Obermeier, Birgit
    Kryzer, Thomas J.
    Sano, Yasuteru
    Kanda, Takashi
    Lennon, Vanda A.
    Ransohoff, Richard M.
    Bennett, Jeffrey L.
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (397)
  • [9] Sera from neuromyelitis optica patients disrupt the blood-brain barrier
    Shimizu, Fumitaka
    Sano, Yasuteru
    Takahashi, Toshiyuki
    Haruki, Hiroyo
    Saito, Kazuyuki
    Koga, Michiaki
    Kanda, Takashi
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (03): : 288 - 297
  • [10] Sera from neuromyelitis optica patients disrupt the blood-brain barrier
    Shimizu, F.
    Sano, Y.
    Haruki, H.
    Kanda, T.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S330 - S331